In vivo studies on striatal dopamine D1 and D2 site binding in L- dopa-treated Parkinson's disease patients with and without dyskinesias

Neurology

Volumn 49, Issue 3, 1997, Pages 717-723

  Turjanski, Nora ^a   Lees, A J ^b   Brooks, D J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; PLACEBO; RACLOPRIDE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE BRAIN LEVEL; DYSKINESIA; HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RECEPTOR AFFINITY; RECEPTOR POTENTIAL;

EID: 0030827709     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.717     Document Type: Article

References (62)

1. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 1993;602:290-303.
2. Bedard PJ, Gomez Mancilla B, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: farts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992; 19:134-137.
3. Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
4. Reches A, Wagner HR, Jackson-Lewis V, Yahlonskaya-Alter E, Fahn S. Chronic levodopa or pergolide administration induces downregulation of dopamine receptors in denervated striatum. Neurology 1984;34:1208-1212.
5. Murata M, Kanazawa I. Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat. Neurosci Res 1993;16:15-23.
6. Fuxe K, Agnati LF, Kohler C, et al. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J Neural Transm [Gen Sect] 1981; 51:3-37.
7. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
8. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
9. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
10. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-933.
11. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
12. Luquin MR, Guillen J, Martinez-Vila E, Laguna J, Martinez Lage JM. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys. Eur J Pharmacol 1994;253: 215-224
13. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978;273:59-61.
14. 2 receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15.
15. 2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30-38.
16. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
17. Shinotoh H, Hirayama K, Tateno Y. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET. Adv Neurol 1993;60:488-493.
18. 2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220-228.
19. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707.
20. Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988;86:291-306.
21. Cash R, Raisman R, Ploska A, Agid Y. Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J Neurochem 1987;49:1075-1083.
22. Reisine TD, Fields JZ, Yamamura HI, et al. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci 1977;21: 335-344.
23. Ahlskog JE, Richelson E, Nelson A, et al. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 1991;30:185-191.
24. Rinne JO, Laihinen A, Lonnberg P, Marjamaki P, Rinne UK. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122.
25. 3H]SCH23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 1985;113:467-468.
26. 18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system. J Neural Transm [Gen Sect] 1990;81:195-213.
27. 1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 1985;114:235-237.
28. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988;35:721-725.
29. Spinks TJ, Jones T, Bailey DL, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992;37:1637-1655.
30. Robb RA. A software system for interactive and quantitative analysis of biomedical images. In: Hohne KH, Fuchs H, Pizer SM, eds. 3D imaging in medicine. NATO ASI Series, 1990: 333-361.
31. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomie dysfunction, and the integrity of the striatal dopaminergic system, in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552.
32. Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11 labelled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54.
33. 2 receptor binding in the living human brain by PET. Science 1986;231:258-261.
34. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52.
35. Lammerstma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage 1996;4:153-158.
36. Guttman M, Seeman P. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. Adv Neurol 1986;45:51-57.
37. Rinne JO, Laihinen A, Nagren K, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 1990;27: 494-499.
38. 11C]raclopride [abstract]. Neurology 1992;42(suppl 3):295-296.
39. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Brain 1993;116:853-867.
40. 2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990;5:55-59.
41. 2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993;8:134-138.
42. 2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and Iodobenzamide I 123. Arch Neurol 1993;50:509-512.
43. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
44. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
45. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. European J Pharmacol 1984;99:167-175.
46. 11C-N-methyl-spiperone. Acta Neurol Scand 1987;75:87-94.
47. 2 receptors. Neurology 1994;44:1325-1329.
48. Playford ED, Brooks DJ. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev 1992;4:144-171.
49. Gifford AN, Gatley SJ, Ashby CR. Endogenously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse 1996;22:232-238.
50. 2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 1986;19: 487-492.
51. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52: 1183-1190.
52. 2 receptor binding in patients with Huntington's disease and other choreas: a PET study. Brain 1995;118: 689-696.
53. Bedard PJ, Blanchet PJ, Calon F, DiPaolo T. The paradox of dyskinesia and wearing-off. A hypothesis based on observations in the MPTP monkey model of parkinsonism [abstract]. Mov Disord 1994;9(suppl 1):153.
54. Gagnon C, Gomez-Mancilla B, Bedard PJ, Di Paolo T. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors. Neurosci Lett 1993;163:31-35.
55. A receptors in the striatopallidal complex. Brain Res 1995;680:43-52.
56. Piccini P, Weeks RA, Burn DJ, Brooks DJ. PET studies on opioid receptor binding in Parkinson's disease patients with and without levodopa-induced dyskinesias [abstract]. Neurology 1996;46(suppl):A454.
57. Greenamyre T. Pharmacological pallidotomy with glutamate antagonists? Ann Neurol 1996;39:557-558.
58. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
59. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
60. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
61. Nutt JG. Levodopa-induced dyskinesia: Review, observations and speculations. Neurology 1990;40:340-345.
62. Pearce RKB, Zeng B-Y, Jenner P, Marsden CD. Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic L-dopa administration [abstract]. Br J Pharmacol 1995;116:78.